| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 3.08 | 0.00 (0.00%) | 1.03 - 3.25 | 220.5 thousand (Below Avg) |
Market data as of 3:59PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 3.05 |
|---|---|
| Previous Close | 3.08 |
| Day's Range | 3.02 - 3.13 |
| Market Cap | 46.9M |
| Avg Volume (10 Day) | 473.3K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.52 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Vermillion Reports First Quarter 2013 Results
PR Newswire - Wednesday 05/15/2013 4:01 PM ET
Vermillion Announces Closing of Equity Financing
PR Newswire - Tuesday 05/14/2013 8:31 AM ET
Vermillion Announces Equity Financing
PR Newswire - Thursday 05/09/2013 8:31 AM ET
Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
PR Newswire - Wednesday 05/08/2013 4:07 PM ET
Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
PR Newswire - Wednesday 05/01/2013 8:31 AM ET
| VRML | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 16.96% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.49 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 22.21 |
| Company | Last | Change |
|---|---|---|
| Chembio Diagnostics Inc | 4.50 | 0.00% |
| Rosetta Genomics Ltd | 4.01 | +0.50% |
| Tekmira Pharmaceuticals Corp | 4.71 | -0.80% |
| Palatin Technologies Inc | 0.64 | +1.59% |
| Atossa Genetics Inc | 5.13 | 0.00% |
Data is delayed by at least 15 min.